Brief report

Francisco Álvarez Lerma¹,²,³ Rosana Muñoz Bermúdez¹ Santiago Grau¹,²,⁴ María Pilar Gracia Arnillas¹,²,³ Luisa Sorlí⁵,⁶ Luis Recasens⁷ Miquel Mico García⁸

Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa

¹Servicio de Medicina Intensiva, Hospital del Mar, Barcelona
²Universitat Autònoma de Barcelona
³Grupo de Investigación en Patología Crítica (GREPAC), IMIM-PRBB, Barcelona
⁴Servicio de Farmacia, Hospital del Mar, Barcelona
⁵Servicio de Enfermedades Infecciosas, Hospital del Mar, Barcelona
⁶Universitat Pompeu Fabra, Barcelona
⁷Servicio de Cardiología, Hospital del Mar, Barcelona
⁸Servicio de Microbiología, Laboratori de Referencia de Catalunya, Barcelona

ABSTRACT

The use of colistin for the treatment of multiresistant bacteria has led to the emergence of colistin-resistant strains of Gram-negative bacilli. Treatment of infections caused by these pan–drug-resistant bacteria is difficult owing to the paucity of effective antibiotics. We report two cases of ventilator-associated respiratory infection caused by pan–drug-resistant, colistin-resistant Pseudomonas aeruginosa that were successfully treated with ceftolozane-tazobactam.

Key words: Ceftolozane-tazobactam, colistin-resistant Pseudomonas aeruginosa, ventilator-associated respiratory infection, ICU

Ceftolozano-tazobactam en el tratamiento de infecciones respiratorias asociadas a ventilación mecánica por Pseudomonas aeruginosa resistente a colistina

RESUMEN

La utilización de colistina para el tratamiento de bacterias multirresistentes ha favorecido la aparición de cepas de bacilos gramnegativos resistentes a dicho antibiótico. El tratamiento de las infecciones producidas por estas bacterias panresistentes es difícil dada la escasez de antibióticos que se pueden emplear en esta situación. Se presentan dos pacientes con infecciones respiratorias relacionadas con ventilación mecánica producidas por una Pseudomonas aeruginosa panresistente y resistente a colistina que fueron tratadas con ceftolozano/tazobactam con buenos resultados.

Palabras clave: Ceftolozano/tazobactam, Pseudomonas aeruginosa resistente a colistina, infecciones respiratorias relacionadas con ventilación mecánica, UCI

INTRODUCTION

Ceftolozane is a new beta-lactam cephalosporin, whose mechanism of action is the same as that of other beta-lactams: it acts on penicillin-binding proteins and inhibits bacterial wall cell synthesis. Tazobactam has very limited antibacterial activity when administered in monotherapy. It inhibits various beta-lactamases, including broad-spectrum and extended-spectrum enzymes. Ceftolozane is active against Escherichia coli, Morganella morganii, Proteus mirabilis, Serratia marcescens, and Salmonella spp., as well as against non-fermenting Gram-negative bacilli especially Pseudomonas aeruginosa. It is the cephalosporin with the strongest activity against this pathogen, since it is stable in the presence of AmpC beta-lactamases and is not affected by the loss of outer membrane porins or by the presence of active efflux pumps. This new antibiotic is eliminated mainly via the kidneys, and its dose must be adjusted in patients with moderate to severe renal failure (estimated creatinine clearance <50 mL/min). The efficacy of ceftolozane-tazobactam has been evaluated in adults in two pivotal phase III trials, and has been authorised for treatment of complicated abdominal infections and urinary tract infections, including pyelonephritis

In recent years, the use of intravenous colistin to treat health care–related infections caused by non-fermenting Gram-negative bacilli, particularly P. aeruginosa and Acinetobacter baumannii, has led to the emergence of colistin-resistant strains. Although the phenomenon is unusual, reports of infections caused by colistin-resistant Gram-negative bacilli treated with various combinations of antibiotics have shown different results. In February 2016, two consecutive patients admitted to the intensive care unit (ICU) of our hospital were diagnosed with ventilation-associated respiratory infections caused by pan–drug-resistant P. aeruginosa, which became resistant to colistin after treatment with this antibiotic and was susceptible to ceftolozane-tazobactam (MIC, 2 mg/L). Consequently, ceftolozane/tazobactam was requested through the
compassionate use program of the Ministry of Health. In the present study, we report the characteristics of the patients, the infection, the pathogen isolated, and changes in the values of inflammatory markers and clinical signs of infection after administration of ceftolozane-tazobactam.

**CASE REPORTS**

Case 1. The patient was a 72-year-old man with no known drug allergies. He had a history of hypertension, diabetes mellitus, peripheral vascular disease with intermittent claudication, chronic obstructive pulmonary disease, and severe ventricular dysfunction caused by extensive necrosis affecting the inferior-lateral cardiac wall that required surgical revascularisation. He also had a 1-year history of arrhythmia due to atrial fibrillation. The patient attended the emergency department in January 2016 with rectal bleeding while taking anticoagulation therapy. Fibre-optic gastroscopy revealed a large clot in the fundus. The patient was intubated during the procedure owing to oxygen desaturation and hypotension and was admitted to the coronary intensive care unit (C-ICU) (APACHE II score, 28). Since the patient remained in cardiogenic shock after bleeding was controlled, pulmonary artery pressure was monitored and inotropic support provided. The clinical course was initially favourable, and inotropic and ventilatory support were withdrawn. Isolation of *P. aeruginosa* in the bronchial aspirate sample (BAS) on admission to the C-ICU was considered to indicate colonisation. After 18 days in the C-ICU, the patient went into hypovolaemic shock (serum haemoglobin, 4.5 g/dL) because of a bleeding ulcer in the antrum, which was resolved with no further complications. The patient also had tubular necrosis, which was managed with renal replacement therapy (1 week). During the fourth week of stay in the C-ICU, the patient had symptoms of tracheobronchitis. Pan-drug-resistant *P. aeruginosa* was isolated from the BAS (table 1), and treatment with nebulised colistin (1 million IU t.i.d.) and meropenem (2 g b.i.d.) was started. Two weeks later, colistin-resistant strains of *P. aeruginosa* were isolated in surveillance samples (rectal swab). Owing to the failure of two attempted extubations, percutaneous tracheostomy was performed at 36 days after admission. Given the previous alteration in renal function and susceptibility to ceftolozane-tazobactam, treatment was started with this antibiotic at doses of 1/0.5 g t.i.d. (first four days), followed by 0.5/0.25 g t.i.d. for a further 10 days. The clinical and microbiological response was favourable, with negative BAS culture before withdrawal of treatment (colistin-susceptible *P. aeruginosa* persisted in the surveillance samples). Figure 1 shows changes in the values of inflammatory markers during treatment with ceftolozane-tazobactam. The patient was decannulated and moved to a conventional ward to continue treatment. He subsequently experienced refractory heart failure that did not respond to medical treatment and died three weeks after discharge from the C-ICU.

Case 2. The patient was a 48-year-old man with no known drug allergies. He had severe alcoholism with a history of hypertension, depressive syndrome, and dilated cardiomyopathy. In January 2016, he was admitted to the C-ICU from another hospital. He was already intubated and ventilated, with a diagnosis of respiratory insufficiency due to influenza A virus pneumonia (treated with oseltamivir, ceftriaxone, and levofloxacin) and haemodynamic instability (treated with vasoactive drugs [norepinephrine]). On admission (APACHE score, Table 1: Antibiotic profile by date of isolation of *P. aeruginosa* in patients treated with ceftolozane-tazobactam

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>≤8 S</td>
<td>≤8 S</td>
<td>16 I</td>
<td>≤8 S</td>
<td>16 I</td>
<td>≤8 S</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>8 I</td>
<td>16 I</td>
<td>32 R</td>
<td>8 I</td>
<td>ND</td>
<td>8 I</td>
</tr>
<tr>
<td>Colistin</td>
<td>≤2 S</td>
<td>≤2 S</td>
<td>≥16 R</td>
<td>≤2 S</td>
<td>4 I</td>
<td>≤2 S</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>2 S</td>
<td>16 R</td>
<td>16 R</td>
<td>16 R</td>
<td>16 R</td>
<td>16 R</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>≤0,5 S</td>
<td>&gt;2 R</td>
<td>≥4 R</td>
<td>&gt;2 R</td>
<td>&gt;4 R</td>
<td>&gt;2 R</td>
</tr>
<tr>
<td>Cefepime</td>
<td>2 S</td>
<td>16 R</td>
<td>16 R</td>
<td>16 R</td>
<td>16 R</td>
<td>16 R</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>2 S</td>
<td>&gt;8 R</td>
<td>≥16 R</td>
<td>&gt;8 R</td>
<td>≥16 R</td>
<td>&gt;8 R</td>
</tr>
<tr>
<td>Imipenem</td>
<td>≤2 S</td>
<td>&gt;8 R</td>
<td>≥16 R</td>
<td>&gt;8 R</td>
<td>≥16 R</td>
<td>&gt;8 R</td>
</tr>
<tr>
<td>Meropenem</td>
<td>≤2 S</td>
<td>&gt;8 I</td>
<td>≥16 R</td>
<td>8 I</td>
<td>4 I</td>
<td>8 I</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>≤8 S</td>
<td>64 R</td>
<td>≥12 R</td>
<td>32 R</td>
<td>≥128 R</td>
<td>32 R</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>≤2 S</td>
<td>&gt;8 R</td>
<td>≥16 R</td>
<td>&gt;8 R</td>
<td>≥16 R</td>
<td>&gt;8 R</td>
</tr>
<tr>
<td>Ceftolozane/tazobactam</td>
<td>ND</td>
<td>ND</td>
<td>2 S</td>
<td>ND</td>
<td>2 S</td>
<td>ND</td>
</tr>
</tbody>
</table>

MIC, minimum inhibitory concentration; BAS, bronchial aspirate; OR, oropharyngeal; ND: not determined; S, susceptible; R, resistant; I, intermediate.
condition and a chest computed tomography scan that revealed bilateral pulmonary opacities, signs of hepatisation, areas of necrosis, and air-fluid levels suggestive of lung abscesses, intravenous colistin was administered (3 million IU t.i.d.) in combination with aztreonam (2 g t.i.d.), meropenem (1 g t.i.d. in extended perfusion), and azithromycin (0.5 g per day). The patient’s renal function deteriorated despite plasma colistin concentrations being within the therapeutic range (C\text{min}, 1.8 mg/L at three days after intravenous administration), and extrarenal clearance techniques were applied because of persistent oligoanuria and anasarca. Percutaneous tracheostomy was performed 22 days after admission because of prolonged intubation.

![Figure 1](image1.png)

**Figure 1** Inflammatory markers during treatment with ceftolozane/tazobactam (case 1)

![Figure 2](image2.png)

**Figure 2** Inflammatory markers during treatment with ceftolozane/tazobactam (case 2)
samples at 12 days after initiation of treatment with colistin revealed *P. aeruginosa* with a MIC of 4 mg/L. Given the altered renal values and persistence of multiple cavitated lesions on the computed tomography scan and after verifying *in vitro* susceptibility to ceftolozane-tazobactam (MIC, 2 mg/L) using microdilution techniques, administration of ceftolozane-tazobactam was started at doses of 0.5/0.25 g t.i.d. Treatment was maintained for 17 days. Subsequent culture of respiratory samples was negative, with good clinical evolution and a return to normal inflammatory marker values (figure 2). The patient subsequently presented with herpes simplex pneumonia, which was treated with acyclovir, and pseudomembranous colitis caused by *Clostridium difficile*, which was treated with oral vancomycin and metronidazole. The patient’s clinical condition improved. After 87 days in the C-ICU, the patient was decannulated and transferred to the ward. Three months after discharge, colonisation by pan–drug-resistant, colistin-susceptible *P. aeruginosa* colonisation (surveillance samples [rectal swab]) persisted, but the patient’s outcome was satisfactory.

**DISCUSSION**

Little experience has been reported with ceftolozane-tazobactam for treatment of infection in critically ill patients. Clinical trials to date have included patients with complicated abdominal and urinary infections for which ceftolozane-tazobactam has been approved. However, the number of critically ill patients included in the trials was very small. Data on ceftolozane-tazobactam in critically ill patients are limited to two studies, in which pharmacokinetic changes affecting the antibiotic are described in patients requiring extrarenal clearance techniques and a letter to the editor reporting three antibiotic failures in patients requiring extrarenal clearance techniques. The dose was that used in a clinical trial evaluating ceftolozane-tazobactam for the treatment of nosocomial pneumonia, namely, 2 g of ceftolozane and 1 g of tazobactam t.i.d. (results forthcoming). The clinical and microbiological response was excellent in both cases: culture of BAS revealed an MIC for ceftolozane-tazobactam of 2 mg/L. The drug was then requested through the compassionate use program of the Ministry of Health.

Ceftolozane-tazobactam was administered intravenously to both patients as a 30-minute bolus (500/250 mg t.i.d.) for at least two weeks. In both cases, the dose administered was higher than the dose recommended in the summary of product characteristics, taking into account renal function and the application of extrarenal clearance techniques. The drug was then used in a clinical trial evaluating ceftolozane-tazobactam for the treatment of nosocomial pneumonia, namely, 2 g of ceftolozane and 1 g of tazobactam t.i.d. (results forthcoming). The clinical and microbiological response was excellent in both cases: culture of BAS was negative, although the surveillance samples indicated the presence of colonisation. No adverse effects were recorded, and renal function recovered in the second patient. Antibiotic therapy was continued.

Our experience shows that ceftolozane-tazobactam could be suitable for the treatment of colistin-resistant *P. aeruginosa* or pan–drug-resistant, colistin-susceptible strains of *P. aeruginosa* in patients with kidney failure or a high risk of kidney failure.

**ACKNOWLEDGEMENTS**

We are grateful to Dr Concepción Segura from the Reference Laboratory of Catalonia for her assistance with identification and conservation of the strains of *Pseudomonas aeruginosa* and to Dr Juan Pablo Horcajada from the Infectious Diseases Service for his critical review of the manuscript.

MSD provided medical writing support but was not involved in the content of the manuscript.

**REFERENCES**


3. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steen-


13. Clinical Trials. Gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia [MK-7625A-008] [ASPECT-NP]. A prospective, randomized, double-blind, multicenter, phase 3 study to assess the safety and efficacy of intravenous ceftolozane/tazobactam compared with meropenem in adult patients with ventilated nosocomial pneumonia. Available at: https://clinicaltrials.gov/show/NCT02070757